Absolue Longevity MD Intercept The Cream
Discover Absolue Longevity MD, our first proactive personalized longevity skincare to reverse your skin’s visible biological age, at every life stage1.
[Early age] Anticipate – [Mid age: 35-55] Intercept – [Mature age] Reset
[Mid age: 35-55] Absolue Longevity MD Intercept The Cream is a new-generation longevity cream that intercepts aging signs as they appear.
Formulated with Mitopure®, A highly pure form of Urolithin-A, a postbiotic widely recognized in the longevity2.
For a formula with targeted efficacy, Mitopure® is combined with the new proprietary and unique Intercept compound. This complex fuses LHA, Matrixyl, Niacinamide, and Rose Pro-Xylane with Taurine to intercept specific visible skin markers according to your visible biological age—the only age you can reverse.
Clinically measured visible and invisible results
– Visible aging markers: +76% skin elasticity in just 4 hours3
– Invisible aging markers: +4 million new surface cells per day4
1Visible biological age defined as signs of aging such as firmness, suppleness, radiance, fine lines, smoothness, etc.
2Absolue Longevity MD provides a topical cosmetic way to combat visible signs of aging. Does not function like Mitopure oral supplement.
3Instrumental test, 4 hours after application
4Clinical study based on exfoliation over 3 weeks vs. untreated skin
Benefits
+76% skin elasticity in just 4 hours1
+30% firmness in just 4 hours1
Up to -41% forehead wrinkles in 12 weeks2
Up to -57% Nasolabial folds in 12 weeks3
+4M new surface cells per day4
2Clinical testing after 12 weeks showed results up to -41% and average results of -27%
3Clinical testing after 12 weeks showed results up to -57% and average results of -30%
4Clinical study based on exfoliation over 3 weeks vs. untreated skin
Ingredients

A postbiotic widely recognized in the longevity field

A powerful peptide complex known to help reduce the appearance of wrinkles

Known to help promote surface cell turnover & fine lines








Reviews
There are no reviews yet.